Mucuna pruriens/Velvet Bean Cancer Research Results

MP, Mucuna pruriens/Velvet Bean: Click to Expand ⟱
Features:

Mucuna pruriens - Velvet Bean, Kapikacchu

Type: Botanical extract / L-DOPA-rich medicinal seed

Active Constituents: L-DOPA (levodopa), flavonoids, phenolic compounds, alkaloids, fatty acids, and other bioactive constituents.

Function: Mucuna pruriens is notable for its naturally high L-DOPA content and has dopaminergic, antioxidant, mitochondrial, anti-inflammatory, and neuroprotective effects. Whole-seed extracts also contain additional constituents that may modify the effects of L-DOPA.

Cancer: Emerging experimental evidence suggests antiproliferative, pro-apoptotic, and chemosensitizing effects in selected cancer models, although the cancer evidence is less extensive than its neurological literature.

Alzheimer's Disease: Preclinical evidence supports antioxidant, mitochondrial, anti-inflammatory, and neuroprotective effects relevant to neurodegeneration, although Mucuna pruriens is much more strongly established in Parkinson's disease research than in Alzheimer's disease.

Mucuna pruriens/Velvet Bean — Mucuna pruriens is a tropical leguminous medicinal plant whose seeds are naturally rich in L-DOPA (levodopa), together with phenolic compounds, flavonoids, alkaloids, proteins/peptides, fatty acids, and other phytochemicals. It is formally classified as a botanical medicinal product / L-DOPA-rich seed preparation and is commonly abbreviated MP or MPE for Mucuna pruriens extract. The seed typically contains approximately 4–6% L-DOPA, although concentrations vary substantially by cultivar, processing, and commercial extract standardization. Its best-established pharmacological identity is as a natural oral source of levodopa for Parkinson's disease; anticancer activity remains experimental and appears to depend strongly on the particular extract or constituent studied.

Primary mechanisms (ranked):

  1. Suppression of prolactin-driven PRLR/JAK2/STAT5A signaling, with downstream cyclin D1 suppression and reduced proliferation in prolactin-responsive breast cancer models.
  2. Induction of apoptosis, DNA damage, and cell-cycle arrest in selected cancer cell models.
  3. Cisplatin chemosensitization in prolactin-associated breast cancer, including suppression of prolactin-mediated resistance and reduced glutathione-S-transferase activity.
  4. Antiproliferative activity of non-L-DOPA constituents, including Mucuna-derived peptide fractions and isoquinoline alkaloids, indicating that whole-seed activity cannot be attributed to L-DOPA alone.
  5. Modulation of p53 and other apoptosis-related pathways in colorectal cancer models.
  6. Antioxidant and cytoprotective actions, including reduced oxidative stress in non-malignant and neuronal models; these effects are secondary and should not be assumed to mediate the anticancer activity.

Bioavailability / PK relevance: Oral pharmacology is dominated by L-DOPA. Natural seed preparations can deliver pharmacologically significant levodopa, but exposure varies markedly with seed L-DOPA content, processing, gastrointestinal absorption, peripheral decarboxylation, food intake, and whether a peripheral DOPA-decarboxylase inhibitor is coadministered. Clinical studies demonstrate measurable and sometimes substantial systemic levodopa exposure from roasted seed powder. Commercial Mucuna supplements show large discrepancies in actual L-DOPA content, making dose equivalence unreliable unless the preparation is analytically standardized. The PK of the anticancer peptide, alkaloid, and polyphenolic fractions is substantially less established.

In-vitro vs systemic exposure relevance: Most anticancer evidence uses crude seed extracts, isolated fractions, or purified constituents at concentrations not directly translatable to an oral Mucuna dose. Colorectal cancer growth inhibition has been reported at approximately 131–247 µg/mL crude extract, while active hepatocellular-carcinoma peptide fractions showed IC50 values in the tens of µg/mL range. There is no evidence that these concentrations of the relevant intact extract constituents are achieved systemically after normal oral supplementation. In contrast, systemic L-DOPA exposure after oral Mucuna is well demonstrated. Therefore, the prolactin/dopaminergic mechanism has greater translational plausibility than direct systemic cytotoxicity from crude extract.

Clinical evidence status: Cancer: preclinical only; cell-culture studies and limited animal evidence, with no established anticancer RCT or clinical adjunct indication. Parkinson's disease: human clinical evidence including randomized crossover studies and a 12-month randomized phase-2 trial showing clinically meaningful dopaminergic activity. Mucuna is not an established cancer therapy. Safety should be considered pharmacologically similar to levodopa exposure: gastrointestinal effects, orthostatic effects, dyskinesia, neuropsychiatric effects, and dopaminergic drug interactions are relevant. Raw or improperly prepared seeds can cause substantial gastrointestinal and neurologic toxicity.

Mechanistic Effects in Cancer

Rank Pathway / Axis Cancer Cells Normal Cells Primary Effect Notes / Interpretation
1 Prolactin PRLR JAK2 STAT5A PRL ↓; JAK2 ↓; STAT5A ↓ Not established ↓ proliferative signaling Best-defined anticancer mechanism; demonstrated particularly in PRL-expressing T47D and MCF-7 breast cancer cells. Activity of whole Mucuna extract exceeded L-DOPA alone in the reported model.
2 Cyclin D1 Cell Cycle Cyclin D1 ↓; G1 arrest ↑ Not established ↓ proliferation Downstream consequence of PRL/JAK2/STAT5A suppression in breast cancer and accompanied by reduced colony formation.
3 Apoptosis and DNA Damage Apoptosis ↑; DNA damage ↑ Low toxicity reported with some fractions ↑ cancer-cell death Observed with seed extract in breast and colorectal cancer models and with selected peptide fractions in hepatocellular carcinoma. Effects are preparation-dependent.
4 Cisplatin Chemosensitization Cisplatin sensitivity ↑ Not established ↓ chemoresistance Mucuna extract reversed PRL-associated cisplatin resistance in breast cancer cells. This remains an in-vitro observation and is not clinically established.
5 Glutathione S Transferase GST activity ↓ Not established ↑ cisplatin effectiveness Reported during combination treatment in the breast cancer model and proposed to facilitate platinum-induced DNA injury. This should not be generalized to systemic glutathione depletion.
6 p53 Apoptotic Signaling p53 ↑ Not established ↑ apoptotic susceptibility A modest increase in p53 expression was reported in COLO-205 colorectal adenocarcinoma cells following seed-extract treatment.
7 Non L-DOPA Peptide Cytotoxicity Proliferation ↓ Relative resistance ↑ Selective growth inhibition Pepsin-pancreatin-derived 5–10 kDa peptide fractions inhibited several hepatocellular carcinoma lines at substantially lower concentrations than required for toxicity in the tested normal cell line.
8 Isoquinoline Alkaloid Activity Proliferation ↓ Insufficient data ↓ tumor-cell growth An isolated tetrahydroisoquinoline derivative from Mucuna seeds showed antiproliferative activity against Huh-7 hepatocellular carcinoma cells, supporting activity from constituents other than L-DOPA.
9 Oxidative Stress Modulation ↔ (context-dependent) ROS ↓; antioxidant defenses ↑ Cytoprotection in non-malignant models Mucuna frequently shows antioxidant activity and can reduce experimentally induced ROS in normal or neuronal cells. A consistent cancer-selective ROS increase has not been established, so ROS should not be listed as a primary anticancer mechanism.
10 Clinical Translation Constraint Direct anticancer exposure uncertain L-DOPA exposure clinically significant Limits translation Cancer studies use heterogeneous extracts and relatively high in-vitro concentrations. Oral L-DOPA is bioavailable, but systemic exposure to the anticancer peptide, alkaloid, and polyphenolic fractions is poorly characterized. No clinical anticancer efficacy has been demonstrated.


Scientific Papers found: Click to Expand⟱
8918- MP,  Cisplatin,    Mucuna pruriens (L.) DC chemo sensitize human breast cancer cells via downregulation of prolactin-mediated JAK2/STAT5A signaling
- in-vitro, BC, T47D - in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-231
Dose?, TumCP↓, DNAdam↑, TumCCA↑, PRL↓, JAK2↓, STAT5↓, cycD1/CCND1↓, ChemoSen↑,
8919- MP,    Antineoplastic Effects of Mucuna pruriens Against Human Colorectal Adenocarcinoma
- in-vitro, CRC, COLO205
*AntiDiabetic↑, *antiOx↑, *antiNeop↑, antiOx↑, Dose↝, Apoptosis↑, TumCCA?,
8920- MP,    Therapeutic peptides of Mucuna pruriens L.: Anti‐genotoxic molecules against human hepatocellular carcinoma and hepatitis C virus
- in-vitro, Liver, HepG2 - in-vitro, HCC, SMMC-7721 cell - in-vitro, HCC, QGY-7703
TumCD↑, Dose↝, *DNAdam↓,
8921- MP,    “To Bean or Not to Bean”: Therein lie the hype and the hope. Advice to people with Parkinson in my clinic about Mucuna pruriens
- Review, Park, NA
*eff↑, *toxicity↝, *toxicity↝, *Dose↝,
8922- MP,    A Comprehensive Review of the Therapeutic Potential of Mucuna Pruriens
- Review, Park, NA
*Inflam↓, *AntiBio↑, *neuroP?, *Ingr↝, *Ingr↝, *AntiDiabetic↑, *hepatoP↑, *Imm↑, *Dose?, *neuroP↑, *glucose↓,
7368- RS,  Amla,  CS,  Pom,  MP  Natural angiotensin converting enzyme inhibitors: A safeguard against hypertension, respiratory distress syndrome, and chronic kidney diseases
- Study, Nor, NA
*ACE/ACE1↓,

Showing Research Papers: 1 to 6 of 6

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,   TumCD↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

JAK2↓, 1,   STAT5↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

cycD1/CCND1↓, 1,   TumCCA?, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

TumCP↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

PRL↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 1,   Dose?, 1,   Dose↝, 2,  
Total Targets: 14

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

glucose↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Imm↑, 1,   Inflam↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

ACE/ACE1↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose?, 1,   Dose↝, 1,   eff↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiDiabetic↑, 2,   antiNeop↑, 1,   hepatoP↑, 1,   neuroP?, 1,   neuroP↑, 1,   toxicity↝, 2,  

Infection & Microbiome(tgid=24) ⓘ

AntiBio↑, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↝, 2,  
Total Targets: 17

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:445  Target#:%  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page